Apama Medical Announces Claim Coverage In China For Electrode-Based Ablation Balloon For The Treatment Of Atrial Fibrillation (AF) - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Apama Medical Announces Claim Coverage In China For Electrode-Based Ablation Balloon For The Treatment Of Atrial Fibrillation (AF)

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Shifamed

CAMPBELL, Calif., Feb. 18, 2014 /PRNewswire/ -- Apama Medical, a privately held medical device company formed by Shifamed's medical incubator, today announced receipt of a Chinese notice of allowance for claims covering their low profile electrode assembly that enables the attachment of flexible electrodes to an ablation balloon for energy delivery and monitoring. The Chinese patent will complement an existing patent (U.S. Patent No. 8,295,902) giving Apama broad claim coverage for electrode-based ablation balloons in the US and China for the treatment of atrial fibrillation (AF). Utilizing this patented electrode technology enables Apama to design the only ablation catheter that performs a full pulmonary vein (PV) ablation and rotor ablation in a single-shot.

"Accurate energy delivery and monitoring are a challenge during ablation procedures since success often depends on a multitude of discrete catheter manipulations," stated Amr Salahieh, Apama President and CEO. "Our proprietary design offers multipoint, customizable single-shot ablation and eliminates the need for excessive catheter rotations and serial point ablations. This simplifies the current procedure and reduces time, which allows for more patients to be treated."

The global electrophysiology (EP) mapping and ablation market is estimated to reach $4.3B in 2017 and is the fastest growing Cardiac Rhythm Management market segment. Worldwide catheter based AF ablation is estimated to grow from 180,000 procedures in 2009 up to 827,000 procedures by 2017. Fundamental barriers to adoption of AF ablation procedures have been attributed to technical complexity and length of procedure time. As a result, there is a large underserved market.

Apama Medical, a portfolio company of Shifamed, holds the exclusive, worldwide license for EP applications.

About Apama Medical
Apama Medical is a privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical device incubator. To learn more about Apama Medical, please visit www.apamamedical.com.

About Shifamed
Shifamed LLC is a privately held medical technology incubator focused on developing new medical products from concept to commercial release. To learn more about Shifamed, please visit www.shifamed.com.

MEDIA CONTACT:
Katie Arnold
SPRIG Consulting LLC
(408) 805-0520
katie@sprigconsulting.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.